Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAGE-319
- Development stage
- Phase 1
- Lead developer
- Sage Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SAGE-319 is an oral, small molecule drug that acts as an extrasynaptic-preferring positive allosteric modulator (PAM) of GABAA receptors. It is designed to enhance GABAergic neurotransmission by selectively modulating extrasynaptic GABAA receptors, which are implicated in disorders associated with GABA hypofunction. The drug is being developed primarily for the treatment of behavioral symptoms in neurodevelopmental disorders and social behavior disorders such as autism spectrum disorder and fragile X syndrome. Developed by Sage Therapeutics, SAGE-319 represents a novel pharmacological approach targeting the central nervous system to improve social interaction deficits and other behavioral symptoms linked to impaired inhibitory signaling.
- Other names
- SAGE-319SAGE319SAGE 319
02
Targets
GABRR (GABA-A receptor subunit rho)GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)
Beyond the preview
Go deeper on SAGE-319.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAGE-319.